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Background and Objective: Recently, use of prescription opioids
(POs) has increased; non‐medical PO (NMPO) use is linked to
overdose. NMPO use is common among individuals prescribed
opioids for pain, and those in substance use disorder (SUD) treatment
with pain could be at increased risk for unintentional overdose due to
NMPO use. We examined associations between pain, NMPO use, and
overdose among SUD treatment patients.
Methods: Among 342 patients at a residential SUD treatment center,
logistic regression examined the association of overdose with pain,
adjusting for substance use, suicide attempts, and demographics.
Results: Painwas positively related toNMPOuse. Heroin use, suicide
attempts, pain, and NMPO use were positively associated with
overdose; but NMPO use attenuated the pain‐overdose relationship.
Conclusions: The relationship between pain and overdose among
substance users may be, in part, explained by the association between
pain and heavy NMPO use. (Am J Addict 2014;23:41–47)
BACKGROUND AND OBJECTIVES
Overdose in Substance Using Individuals
Individuals with substance use disorders (SUDs) are at
elevated risk for overdose.1–8 Among SUD treatment patients,
history of non‐fatal overdose is relatively common with the
prevalence of prior overdose ranging from 24% to 61%1,9–12
and research regarding unintentional overdose decedents
suggests that most have a history of substance abuse.13
Patients completing SUD treatment are at particularly elevated
risk for post‐treatment overdose, potentially due to decreased
tolerance.14,15 Thus, it is important to identify potential
modiﬁable risk factors for unintentional overdose among
SUD patients.
Pain and Prescription Opioid Use as Risk Factors for
Overdose
Prior work regarding risk factors for post‐treatment
overdose found that higher self‐reported pain levels during
the year before treatment predicted a greater likelihood of post‐
treatment overdose, even after controlling for history of
overdose, sexual abuse, suicide attempts, and demographics.9
Chronic pain may increase overdose risk because those with
pain may use higher levels of prescription opioid (PO) pain
medications due to analgesic effects. Thus, overdoses among
individuals using POs may have occurred in part due to
increasing use of their prescribed pain medications, and prior
research supports increased overdose risk at higher prescribed
doses of POs.16,17 This notion is consistent with evidence that
SUD treatment patients with chronic pain report more use of
heroin and other opioids than those without pain,18,19
potentially as an attempt to self‐medicate. This is also
consistent with Ballantyne and Mao’s20 framework for
understanding adverse outcomes of opioid therapy. Speciﬁcal-
ly, they theorize that prolonged use of opioids results in cellular
and intracellular changes that lead to pharmacologic tolerance
and hypersensitivity to pain (ie, hyperalgesia). Tolerance and
hyperalgesia then contribute to the patient’s perception that the
current dose of POs is not sufﬁcient for pain relief, which
results in dose escalation, thereby increasing risk for adverse
outcomes such as overdose.
In contrast to the theorized model, in analyses conducted by
Britton et al.9 with SUD treatment patients, opioid use was only
associated with post‐treatment overdose at the bivariate level
and was not signiﬁcant when adjusting for other factors.
However, the measure of opioid use in this study did not
distinguish between heroin and POs, and only assessed
whether opioids were a participant’s “preferred substance of
use,”which may not identify patients with pain conditions who
are prescribed opioids but use them non‐medically. A previous
investigation also demonstrated that a single‐item measure of
non‐medical PO (NMPO) use identiﬁes fewer non‐medical
users compared to several items designed to assess various
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types of non‐medical use (eg, taking more than prescribed,
“borrowing” medications).21
Although prior research indicates a link between heroin use
and overdose,22,23 less is known about risks for overdose due to
use of POs, which are pharmacologically similar to heroin.
However, the increase in medical use of POs has been tied to
overdose trends in that POs surpassed heroin (and cocaine) as
the leading cause of fatal overdose as PO prescribing
increased.24–26 Among non‐treatment samples5,13,27 investi-
gations have also demonstrated links between NMPO use and
non‐fatal overdose. Within SUD treatment, NMPO use is
relatively common among patients prescribed opioids for
pain.28–32
Similar to other deﬁnitions,33–35 we deﬁne NMPO use as
any use of POs in excess of how they were prescribed (eg,
using more than prescribed or longer than prescribed) and/or
use for reasons other thanmedical care (eg, to get high, relax, or
sleep). Given the prevalence of NMPO use among pain patients
and the relationship between POs and overdose5,24,25,27 it is
possible that, among those in SUD treatment, NMPO use could
account for the relationship between pain and non‐fatal
overdose. Further, those who engage in frequent (ie, heavier)
NMPO use may be at a higher overdose risk than those who
only occasionally use POs.
The Present Study
Considering the previous research establishing relation-
ships between pain and opioid use with overdose and
Ballantyne and Mao’s20 model, the present study adds to
current understanding by utilizing data from a SUD treatment
sample to explore relationships between pain, NMPO use, and
overdose. Speciﬁcally, because pain may lead to NMPO use,
we were interested in evaluating heavy (ie, more frequent)
NMPO use in relation to pain and overdose. Furthermore,
because prior work9 did not ﬁnd a signiﬁcant relationship
between opioid preference and overdose when controlling for
other factors, we explored the association of heavy NMPO use
with overdose; such use may be a stronger correlate of
overdose given how common NMPO use is among individuals
in SUD treatment. Therefore, among adults in SUD treatment,
we examined the hypotheses that pain and NMPO use would
be associated with increased likelihood of lifetime overdose.
Because prior research has demonstrated relationships between
suicide and depressive symptoms with overdose,1,9 we also
evaluated the relationships between suicide attempt history and
overdose history.
METHODS
Procedure and Study Setting
We examined data from a pilot data collection used in the
formation of a randomized control trial examining the impact
of a pain‐related cognitive‐behavioral intervention for sub-
stance users. Men and women age 18 or older were recruited
over 1 year (2008–2009) from a large residential SUD
treatment center serving the Detroit and Flint, Michigan areas.
This center provides separate residential services to approxi-
mately 420 men and 210 women per year who stay for
approximately 60 days; approximately 77% complete their
course of treatment.
On recruitment days, research staff made announcements
about the research study at the study site’s morning meeting
for all patients. Patients were encouraged to attend screening
sessions during their daily free time. This process allowed us
to screen a large number of patients without interfering with
their treatment; however, it does not allow comparison
between participants and non‐participants/refusals on vari-
ous characteristics, nor does it allow for assessing reasons
for not participating. Individuals who attended a screening
session were given information about the protocol, gave
written informed consent, and completed self‐administered
screening questionnaires in 45–60 minutes. Exclusion crite-
ria included: inability to speak or understand English,
inability to provide written consent, or the research staff’s
observation of acute psychotic symptoms. No potential
participants were excluded at screening. Participants were
compensated with a $10 gift card. Approval for this study
was provided by the Institutional Review Board at the
University of Michigan.
Measures
The screening questionnaire consisted of self‐administered
surveys measuring demographics, pain, mental and physical
health functioning, and substance use history. The following
measures were utilized in the present analyses:
Pain
Participants’ average pain level during the previous week
was assessed using the 11‐point Numeric Rating Scale of
pain intensity36 (PI‐NRS) which read: “On a scale of 0–10,
with 0 being no pain at all and 10 being the worst possible
pain, how would you rate your pain on the average during
the last week?” This measure has external validity and can
detect clinically meaningful changes in subjective pain
intensity.36
Non‐Medical Prescription Opioid Use
Participants completed the 17‐item Current Opioid Misuse
Measure37 (COMM) which assesses self‐reported frequency of
thoughts and behaviors pertaining to aberrant PO use in the
30 days prior to SUD treatment. Response choices range from 0
(never) to 4 (very often). The COMM has demonstrated
internal consistency and test–retest reliability.37,38 As de-
scribed by Price et al.,21 we created a variable measuring
NMPO use relevant to individuals in SUD treatment using the
six items assessing: going to someone other than one’s
prescribing physician, taking medications differently than
prescribed, taking medications belonging to someone else,
taking more than prescribed, borrowing from someone else,
and using pain medicine for symptoms other than pain. Internal
consistency reliability among these items was .93.
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In previous work with this sample, Price et al.21 used any
positive response (ie, 1–4) on any of these six items to
denote non‐medical use and found that use of this criterion is
more sensitive to detection of NMPO use than a single‐item
measure. Because we were evaluating heavy NMPO use, we
created a new metric for this measure by deﬁning heavy use
as a response of “very often” (ie, 4) on any one of these six
questions. Thus, for our analyses, participants’ responses
were dichotomized into presence or absence of past 30‐day
heavy NMPO use.
Substance Use and Overdose History
We used items from the self‐report Addiction Severity
Index39,40 (ASI) to assess substance use history. Participants
reported the number of years in their lifetimes they had used
several substances, including alcohol, heroin, and cocaine. In
addition to including years of alcohol use in our analyses,
we included lifetime heroin and cocaine use because, aside
from prescription opioids, these two substances have been
repeatedly related to increased risk for overdose.2,6,25,41
Although not validated in the self‐report version of the ASI,
we also included an item from the interviewer–administered
ASI42 asking, “How many times have you overdosed on
drugs?” for which participants wrote in the number of times
they had overdosed. Participants’ responses on the heroin,
cocaine, and overdose items were dichotomized (yes/no) for
a history of any lifetime overdose or use of heroin or
cocaine.
Suicide Attempts
To assess suicide attempt history, we used a single item from
the Beck Scale for Suicide Ideation–Self‐Report.43,44 Partic-
ipants indicated if they had attempted suicide never, once, or at
least twice. For the present analyses, participants’ responses
were dichotomized into ever/never attempting suicide.
Data Analysis
Chi‐square analyses and independent samples t‐tests were
used to evaluate bivariate associations between independent
variables (ie, age, gender, race, education, alcohol use, heroin
use, cocaine use, pain, suicide attempts, and NMPO use) and
overdose history. We utilized Holmbeck’s45 three‐step method
to assess relationships among heavy NMPO use, pain, and
overdose: (1) using logistic regression with simultaneous entry
of independent variables, we evaluated the association of pain
ratings, gender, age, education (high school/less than high
school), race (Caucasian/non‐Caucasian), years of regular
alcohol use, lifetime heroin use (ever/never), lifetime cocaine
use (ever/never), and lifetime suicide attempts (ever/never)
with heavy NMPO use (present/absent); (2) controlling for the
same demographic and substance use variables, we evaluated
the association of pain ratings with non‐fatal overdose (ever/
never); and (3) we separately assessed for a potential mediating
effect of heavy NMPO use by utilizing the same model
described in Step 2 with the addition of heavy NMPO use as an
independent variable.
RESULTS
Patient Characteristics
Participants were 326 patients enrolled at the study site who
provided complete data on all study variables (351 were
screened; 25 had missing data on relevant variables and were
not included in analyses). The sample of 326 was 75.5% male
with a mean age of 35.1 years (SD ¼ 10.6). Most were
Caucasian (65.3%); African Americans (26.7%), Hispanic/
Latinos (1.5%), and other races/ethnicities (6.5%) were also
represented. Participants had an average of 11.8 years of
education (SD ¼ 2.1), most were unemployed (72.8%), and
17.0% were currently married or living with a partner. Other
sample characteristics are provided in prior publications.21,46
Ninety‐four (28.8%) participants reported a lifetime history
of overdose and 74 (22.4%) reported heavy NMPO use in the
month preceding treatment. Figure 1 depicts the proportion of
individuals, by overdose history, who endorsed “very often”
engaging in each of six items assessing NMPO use (a full
summary of item responses among this sample is available in a
prior publication20). Overdose history differed across groups
based on gender, race, heroin use, cocaine use, suicide
attempts, and presence/absence of past 30‐day heavy NMPO
misuse (Table 1). Age, education, pain, and years of alcohol
use did not signiﬁcantly differ by overdose history.
Multivariable Analyses
Following Step 1 in the analysis plan, the logistic regression
model testing the association between pain ratings and heavy
NMPO use was statistically signiﬁcant (p < .001; Table 2,
Model 1). Those who had ever used heroin (OR ¼ 5.07; 95%
CI ¼ 2.53–10.14) and those with a history of at least one
suicide attempt (OR ¼ 2.59; 95%CI ¼ 1.40–4.78) were more
likely to have reported heavy NMPO use. Higher pain ratings
were also associated with increased odds of heavy NMPO use
(OR ¼ 1.31; 95% CI ¼ 1.16–1.48).
FIGURE 1. Percent of participants, by overdose (OD) history, who
reported “very often” to items assessing non‐medical prescription
opioid use.
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TABLE 1. Associations of demographics, substance use, and pain ratings with lifetime history of overdose
Characteristic
Lifetime history of overdose
Test statistic and significance level
No (n ¼ 232) Yes (n ¼ 94)
N(%) or M (SD) N(%) or M (SD)
Age 35.8 (10.2) 33.5 (11.2) t(324) ¼ 1.78, p ¼ .08
Years of regular alcohol use 11.0 (10.1) 11.4 (11.0) t(324) ¼ 0.31, p ¼ .75
Gender
Males 184 (74.8%) 62 (25.2%) x2(1) ¼ 6.44, p < .05
Females 48 (60.0%) 32 (40.0%)
Race
Caucasian 136 (63.9%) 77 (36.2%) x2(1) ¼ 16.03, p < .001
Non‐Caucasian 96 (85.0%) 17 (15.0%)
Education
High school 157 (73.7%) 56 (26.3%) x2(1) ¼ 1.94, p ¼ .16
Less than high school 75 (66.4%) 38 (33.6%)
Lifetime suicide attempt
Yes 48 (52.2%) 44 (47.8%) x2(1) ¼ 22.53, p < .001
No 184 (78.6%) 50 (21.4%)
Lifetime heroin use
Yes 42 (41.6%) 59 (58.4%) x2(1) ¼ 62.40, p < .001
No 190 (84.4%) 35 (15.6%)
Lifetime cocaine use
Yes 129 (63.6%) 74 (36.5%) x2(1) ¼ 15.22, p < .001
No 103 (83.7%) 20 (16.3%)
Past 30‐day heavy non‐medical use of prescription opioids
Yes 29 (39.7%) 44 (60.3%) x2(1) ¼ 45.31, p < .001
No 203 (80.2%) 50 (19.8%)
Past‐week pain level 3.7 (3.0) 4.3 (2.8) t(324) ¼ 1.71, p ¼ .09
TABLE 2. Summary of logistic regression analyses evaluating associations of pain and heavy non‐medical opioid use with overdose (N ¼ 326)
Independent variables
Model 1: Predicting
heavy non‐medical
prescription opioid use
Model 2: Predicting
lifetime overdose
Model 3: Predicting
lifetime overdose
OR (95% CI) OR (95% CI) OR (95% CI)
Female 1.42 (0.74–2.73) 0.93 (0.48–1.80) 0.90 (0.46–1.77)
Caucasian 1.24 (0.59–2.61) 2.19 (1.09–4.40) 2.25 (1.09–4.63)
Age 0.98 (0.94–1.01) 1.00 (0.96–1.03) 1.00 (0.96–1.04)
High school education 0.64 (0.34–1.22) 0.52 (0.28–0.96) 0.55 (0.29–1.04)
Lifetime suicide attempt 2.59 (1.40–4.78) 2.58 (1.43–4.67) 2.23 (1.20–4.12)
Years of regular alcohol use 1.00 (0.96–1.04) 1.03 (0.99–1.06) 1.03 (0.99–1.06)
Lifetime heroin use 5.07 (2.53–10.14) 6.93 (3.61–13.32) 5.42 (2.76–10.64)
Lifetime cocaine use 1.19 (0.60–2.36) 1.72 (0.89–3.32) 1.72 (0.88–3.36)
Past week pain rating 1.31 (1.16–1.48) 1.11 (1.00–1.23) 1.07 (0.96–1.19)
Past 30‐day heavy non‐medical
prescription opioid use
— — 2.99 (1.53–5.84)
Model x2(9) ¼ 76.61 Model x2(9) ¼ 92.34 Model x2(10) ¼ 102.67
p < .05; p < .01; p < .001; Boldface type indicates statistically signiﬁcant results during the review process.
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In Step 2 of the analysis, the logistic regression model
evaluating associations of demographic variables, cocaine and
heroin use, and pain with overdose was also signiﬁcant
(p < .001; Table 2, Model 2). In this model, heroin use
(OR ¼ 6.93; 95% CI ¼ 3.61–13.32) and higher pain ratings
(OR ¼ 1.11; 95% CI ¼ 1.00–1.23) both increased the odds of
participants reporting an overdose. In addition, having a high
school education or greater was associated with decreased odds
of reporting an overdose (OR ¼ 0.52; 95% CI ¼ 0.28–0.96),
whereas Caucasian race (OR ¼ 2.19; 95% CI ¼ 1.09–4.40)
and history of suicide attempt (OR ¼ 2.58; 95% CI ¼ 1.43–
4.67)werebothassociatedwith increasedoddsofprioroverdose.
In Step 3, when heavy NMPO use was added as a dependent
variable and a separate analysis was conducted, the model was
also signiﬁcant (p < .001; Table 2, Model 3). However, the
association of pain with overdose was no longer signiﬁcant
(OR ¼ 1.07; 95% CI ¼ 0.96–1.19) with the inclusion of PO
use in the model, which was associated with increased odds of
prior overdose (OR ¼ 2.99; 95% CI ¼ 1.53–5.84). In this
model, heroin use (OR ¼ 5.42; 95% CI ¼ 2.76–10.64),
suicide attempts (OR ¼ 2.23; 95% CI ¼ 1.20–4.12), and
Caucasian race (OR ¼ 2.25; 95% CI ¼ 1.09–4.63) also
continued to be signiﬁcantly associated with overdose.
DISCUSSION
Prior overdoses were relatively common in these SUD
treatment patients. Over 28% reported at least one lifetime
overdose, which is within the range of 24–61% reported in
other SUD treatment samples.1,9–12 Consistent with prior
research and theory,5,20,24–27 heavy NMPO use was associated
with overdose when accounting for demographics, history of
suicide attempts, and other substance use. Those with higher
pain ratings were also more likely to report an overdose;
however, this association was reduced when heavy NMPO use
was included in our model.
That pain was associated with NMPO use is consistent with
prior work evaluating substance users’ non‐medical use of POs
and benzodiazepines.47 The observed relationship between
pain and overdose was also consistent with a prior prospective
study of patients who completed SUD treatment.9 Our results
differ from those of Britton et al.9 because they only found a
bivariate association between opioid preference and overdose
risk, which became non‐signiﬁcant in multivariate analyses.
Using an expanded measure of NMPO use, the current results
suggest that such use could help explain why individuals with
pain are at elevated overdose risk. Although prior research has
identiﬁed that males have a higher likelihood of non‐fatal
overdose,5,9 in our sample, gender was signiﬁcantly related to
overdose in bivariate analyses, but not in multivariable models.
This inconsistency may be due to the relatively small
proportion of females in our sample.
The present investigation addresses a gap in the literature by
assessing multiple behaviors characteristic of NMPO use, and
these results have implications for assessment, intervention,
and overdose prevention. These ﬁndings highlight the need for
assessing overdose history, including speciﬁc substances used
prior to overdose, at SUD treatment entry, given the notable
prevalence of overdose among individuals in SUD treatment
and that prior overdose is the strongest predictor of future
overdoses.48 In evaluating overdose risk among SUD
treatment patients, assessors may beneﬁt from asking not
only about recent frequency of or lifetime history of opioid use,
but also about pain levels, pain treatment, and the several types
of NMPO use included in this study’s measure of NMPO use.
Like individuals who reported heavy NMPO use, partic-
ipants who used heroin were at increased risk for overdose.
Together, these ﬁndings likely reﬂect the heightened risk of
respiratory depression associated with opioids broadly com-
pared to other substances49 and those who use both POs and
heroin could be at a particularly heightened risk. Furthermore,
individualswith ahistoryof suicide attempts had increasedodds
of reporting an overdose. Our data does not allow for
determining intentionality, such as if the overdoses were
attempted suicides; however, this observed relationship also
supports the importance of assessing suicide history in relation
to overdose risk. Future research on overdose should include
thorough assessments of causal substances and intentionality.
Although these ﬁndings are exploratory and cross‐sectional,
they suggest that the relationship between pain and overdose
history among substance users may be, at least in part,
explained by the association between pain and heavy PO use.
Among individuals in SUD treatment, those with chronic pain
may have greater access to POs due to the prescribing of POs
for pain treatment. The hyperalgesia and tolerance that can be
caused by long‐term use of opioids20 could increase the
frequency of heavy NMPO use. Obtaining pain ratings from
individuals entering SUD treatment may help identify those in
need of further assessment, including a more detailed
evaluation of PO use, and who may beneﬁt from targeted
interventions designed to reduce overdose risk and improve
pain management through non‐pharmaceutical treatments.
Results also suggest that coordination between SUD clinicians
and pain care providers may be important for overdose risk
assessment, careful monitoring of PO use, and prevention
interventions. However, future research is needed to under-
stand the contexts surrounding overdose when opioids are
prescribed versus obtained from other sources.
Despite these implications, this exploratory investigation
has several limitations. First, this study was cross‐sectional,
with key variables measured over different time periods (eg,
past‐week pain, 30‐day NMPO use, lifetime overdose), and we
cannot infer causality. We also cannot distinguish the circum-
stances of overdoses reported, and whether variables such as
pain, PO use, and/or suicide attempts were causes of the
reported overdoses. While pain and PO misuse may be
ongoing, their patterns could ﬂuctuate over time and it is not
known whether the variables used in this study represent pain
and substance use proximal to the reported overdoses. Further,
this study is limited in that it could not examine the
relationships of pain and NMPO use with fatal overdose. In
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addition to geographic limitations, participants came from a
single residential SUD treatment program and the reported
associations may differ for individuals in other settings. Our
recruitment procedures could also be subject to a volunteer
bias. Because participants completed measures at treatment
entry, pain ratings could have been inﬂuenced by recent
withdrawal symptoms and may not be a sole reﬂection of a
chronic pain level. Inclusion of comprehensive pain measures
in future research may clarify these relationships.
Furthermore, this investigation is limited in that participants
were asked to report their number of prior drug overdoses, and
not about the causal substance, route of administration, or co‐
ingestion of drugs and alcohol. Thus it is possible that
substances other than POs (eg, benzodiazepines), or co‐
ingestion of substances are responsible for the reported
overdoses. It is also possible that, if analyses were able to be
restricted to overdoses that were only PO‐related, the
associations reported in this investigation could be stronger.
We also did not assess intentionality of the reported overdoses.
However, we were able to include lifetime suicide attempts in
our analyses, and although this variable was related to overdose
history, the associations between overdose, pain, and NMPO
use persisted after this adjustment. Our measure of heavy
NMPO use has not been previously validated and additional
research examining whether this is associated with other key
domains, such as persistence of use and experiencing other
adverse consequences of use, would help to establish the
validity of this measure.
The present results, coupled with those of Britton et al.,9
begin to address a gap in the literature by providing an initial
understandingof the inter‐relationshipsbetweenpain,overdose,
and NMPO use among SUD treatment patients. These results
can inform longitudinal evaluations that can directly assess the
causal mechanisms of overdose. Speciﬁcally, longitudinal data
utilizing a larger sample would allow for examining mediation
and bi‐directionality through a structural equation modeling
approach with reciprocal, cross‐lagged longitudinal paths.
Measures designed to capture more information regarding the
duration ofNMPOuse couldprovide amore complete picture of
how these variables are associated over time. Future research
should also address additional factors that could inﬂuence
overdose, such as route of drug administration, co‐ingestion
with other substances, psychiatric distress, and intentionality. In
addition, future researchshouldevaluatevariableswhichmaybe
associated with pain, such as chronicity, condition, and
treatment history, in relation to risk of overdose among
individuals in SUD treatment. Finally, research is needed to
evaluate whether overdose risk among this population can be
reduced through targeted prevention and intervention.
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